Inhixa (Enoxaparin Sodium)

Enoxaparin Sodium enhances the activity of antithrombin III, which selectively inhibits factor Xa and, to a lesser extent, factor IIa (thrombin). By blocking these key enzymes in the coagulation cascade, the drug reduces thrombin generation and prevents the formation and extension of fibrin clots.

The specific dose of Inhixa is determined by the prescribing clinician based on the patient’s indication, weight, renal function, and clinical condition. Dosing regimens vary for prophylaxis versus treatment, and the prescriber will set the appropriate amount and frequency.

The safety of Enoxaparin Sodium in pregnancy and lactation has not been definitively established. It may be used during pregnancy only when the potential benefit justifies the potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Inhixa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Inhixa (Enoxaparin) is a low molecular weight heparin offering more predictable anticoagulant effects, once‑daily or twice‑daily dosing, and a lower risk of heparin‑induced thrombocytopenia compared with unfractionated heparin. However, dose adjustments may be needed in severe renal impairment, and monitoring is less routine than with unfractionated heparin.

Inhixa should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return to refrigeration promptly.

Inhixa is supplied as a sterile solution for subcutaneous injection. The injection is typically given in the abdomen or thigh, using aseptic technique. The prescriber determines the injection site, volume, and frequency based on the clinical indication and patient characteristics.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, and heparin‑induced thrombocytopenia (HIT), which can paradoxically increase clot formation. Patients should be monitored for signs of unexpected bleeding, sudden drops in platelet count, or neurological changes.

Inhixa should be avoided in patients with a known hypersensitivity to enoxaparin or any component of the formulation, those with active major bleeding, or individuals with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with severe renal impairment unless dose adjustments are made.